Lead Product(s) : 225-Ac PSMA
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Fusion Pharma doses first patient in FPI-2265 prostate cancer trial
Details : FPI-2265 (Ac225-PSMA) is a targeted alpha therapy targeting prostate specific membrane antigen. It is under phase 2/3 development for metastatic castration-resistant prostate cancer.
Product Name : FPI-2265
Product Type : Radiolabelled Compounds
Upfront Cash : Inapplicable
May 13, 2024
Lead Product(s) : 225-Ac PSMA
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 225-Ac PSMA
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : $2,400.0 million
Deal Type : Acquisition
Acquisition of Fusion Pharmaceuticals Completed
Details : Through the acquisition, AstraZeneca will leverage the Fusion pipeline, which includes FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer.
Product Name : FPI-2265
Product Type : Radiolabelled Compounds
Upfront Cash : $2,000.0 million
April 06, 2024
Lead Product(s) : 225-Ac PSMA
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : AstraZeneca
Deal Size : $2,400.0 million
Deal Type : Acquisition